SCHEMBL4518923

SCHEMBL4518923

CN1CCC(NC(=O)Cn2c(-c3ccccc3)c(CN3CCC(c4c(Cl)cccc4Cl)CC3)c3ccccc32)CC1

nearest known ligand 0.48

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 7/20 0.48
ALDH1A1 P00352 3/20 0.45
UBE2N P61088 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
POLB P06746 1/20 0.43
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
LMNA P02545 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4520660 0.92 TSHR (0.49) SIGMAR1ALDH1A1POLBSMN1; SMN2
SCHEMBL4514939 0.88 OPRL1 (0.45) SIGMAR1
Trifluoroacetic Acid SCHEMBL4505995 0.86 UBE2N (0.45) SIGMAR1ALDH1A1UBE2NTDP1POLB
SCHEMBL4521637 0.84 AVPR1B (0.42) SIGMAR1LMNASMN1; SMN2
SCHEMBL4706297 0.84 ALDH1A1 (0.52) SIGMAR1ALDH1A1UBE2NTDP1POLB
SCHEMBL4530222 0.83 OPRL1 (0.44) SIGMAR1ALDH1A1POLBLMNAL3MBTL1
Hydrochloric Acid SCHEMBL4524057 0.83 ALDH1A1 (0.44) SIGMAR1ALDH1A1UBE2NTDP1POLB
SCHEMBL4505447 0.83 HTR2A (0.41) SIGMAR1ALDH1A1SMN1; SMN2
SCHEMBL4522972 0.83 UBE2N (0.45) SIGMAR1ALDH1A1UBE2NTDP1POLB
SCHEMBL4518521 0.82 UBE2N (0.45) SIGMAR1ALDH1A1UBE2NTDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275555-A1 Substituted indole ligands for the ORL-1 receptor BRANE DISCOVERY S.R.L. (IT) 2009-11-05 US claimed
EP-1841755-A1 SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR BRANE DISCOVERY S.R.L. (IT) 2007-10-10 EP claimed
WO-2006070001-A1 SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR BRANE DISCOVERY S.R.L. (IT) 2006-07-06 WO claimed
US-20090275555-A1 Substituted indole ligands for the ORL-1 receptor BRANE DISCOVERY S.R.L. (IT) 2009-11-05 US disclosed
EP-1841755-A1 SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR BRANE DISCOVERY S.R.L. (IT) 2007-10-10 EP disclosed
WO-2006070001-A1 SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR BRANE DISCOVERY S.R.L. (IT) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275555-A1 Substituted indole ligands for the ORL-1 receptor OGFRL1, OPRL1, ORMDL3 SIGMAR1 20/4885ALDH1A1 395/4885UBE2N 2883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.